Enteric fever, primarily caused by Salmonella typhi or Salmonella paratyphi, presents significant challenges to modern healthcare, particularly in developing countries. Effective management requires comprehensive strategies that encompass prevention, timely diagnosis, and appropriate treatment.
Prevention remains the cornerstone of enteric fever management. This includes improving sanitation and access to clean drinking water, food safety measures, and vaccination. Typhoid conjugate vaccines (TCVs) have shown promising results, with WHO recommending their use in endemic areas.
Early and accurate diagnosis is pivotal. Conventional methods like blood culture remain the gold standard but suffer from low sensitivity. Newer diagnostic techniques, such as molecular methods and serological tests, offer improved sensitivity and specificity, albeit at a higher cost.
Treatment primarily involves antibiotic therapy. However, the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains necessitates careful antibiotic selection. Current guidelines recommend third-generation cephalosporins or fluoroquinolones for uncomplicated cases and carbapenems for severe or MDR/XDR cases. Patient monitoring and supportive care are also crucial.
Antimicrobial resistance (AMR) is a significant concern in enteric fever management. Strategies to combat AMR include surveillance for drug-resistant strains, antibiotic stewardship programs, and research into novel antimicrobials and alternative therapies.
In conclusion, effective management of enteric fever necessitates a comprehensive, multi-faceted approach. Preventive measures, improved diagnostics, appropriate treatment protocols, and strategies to address AMR are all integral components. As healthcare professionals, our role extends beyond treating individual patients to influencing public health policies and advocating for necessary resources to combat this global health threat.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation